Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)

{Baseline quantitative [F-18]FDG-PET/CT has been investigated in 108 patients with peripheral T-cell lymphoma. The total metabolic tumor volume (TMTV0) measured at staging was a strong predictor of prognostics. Patients with a high TMTV0 had a poor outcome.Combining TMTV0 with a clinical index (prognostic index for T-cell lymphoma) improved risk stratification.Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. The prognostic impact of total metabolic tumor volume (TMTV0), measured on baseline [F-18]2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography, was evaluated in a retrospective study including 108 PTCL patients (27 PTCL not otherwise specified, 43 angioimmunoblastic T-cell lymphomas and 38 anaplastic large-cell lymphomas). All received anthracycline-based chemotherapy. TMTV0 was computed with the 41% maximum standardized uptake value threshold method and an optimal cut-off point for binary outcomes was determined and compared with others prognostic factors. With a median follow-up of 23 months, 2-year progression-free survival (PFS) was 49% and 2-year overall survival (OS) was 67%. High TMTV0 was significantly associated with a worse prognosis. At 2 years, PFS was 26% in patients with a high TMTV0 (> 230 cm(3)